Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; F-18 fluorothymidine
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- 07 Jul 2022 Status changed from recruiting to completed.
- 14 Jan 2022 Planned End Date changed from 1 Mar 2022 to 1 Nov 2022.
- 14 Jan 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Nov 2022.